Kornimate/medical-research-clean huggingface dataset:
topical ruxolitinib evaluation in vitiligo study 2 (true-v2)

Conditions: Non-segmental Vitiligo

Summary: the purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (bsa).


Eligibility criteria:
key inclusion criteria: * clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% bsa on the face, ≥ 0.5 f-vasi, ≥ 3% bsa on nonfacial areas, ≥ 3 t-vasi, and total body vitiligo area (facial and nonfacial) not exceeding 10% bsa. * agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted. * must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation. key exclusion criteria: * no pigmented hair within any of the vitiligo areas on the face. * other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor). * have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas. * use of protocol-defined treatments within the indicated washout period before baseline.

Keywords: vitiligo non-segmental jak inhibitor
pilot study of oxytocin and microrna identification in naf, serum, and tissue in women with breast cancer

Conditions: Breast Cancer; Ductal Carcinoma in Situ

Summary: the purpose of this study is to examine the genetic material called microrna of three types of specimens from women with breast cancer. the study also seeks to examine the effectiveness of using a new agent called oxytocin to increase the amount of nipple fluid that can be collected during surgery.

vast majority of breast cancers arise from ductal epithelium. ductal cells can be collected through the nipple orifice very early in breast cancer development. the nipple aspirate ﬂuid (naf) can be used to identify biomarkers that predict risk of breast cancer. to date, the biomarkers identified in nipple aspirate ﬂuid (naf) have limited utility due to the large volume of naf required for data analysis. recent studies show intranasal oxytocin's utility in enhancing the yield of nipple aspirate ﬂuid (naf) among healthy, non-lactating female patients as well as those at high risk for breast cancer. this capability is crucial for the analysis of various markers associated with breast disease and cancer such as micrornas. the primary aim of the study is to determine whether the microrna profile characterization is feasible with the collection of tissue, serum and naf in patients with in situ and invasive breast cancer. intranasal oxytocin will be used to enhance ﬂuid yielding of the naf.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ductal carcinoma in situ (dcis) or invasive breast cancer * candidate for breast conserving surgery or mastectomy exclusion criteria: * pregnant women * prior breast cancer diagnosis * adverse reaction to oxytocin in the past

Keywords: breast cancer ductal carcinoma in situ (dcis) oxytocin
effectiveness of walking exercise in improving depression in older adults with major depressive disorder, a pilot study

Conditions: Major Depressive Disorder (MDD)

Summary: 1. this pilot randomized controlled trial aims at investigating the effects of different intensities of aerobic walking exercise to alleviate depression in older adults with major depressive disorder. both baseline and post-intervention measurements will be conducted at the exercise physiology laboratory, division of kinesiology, school of public health, the university of hong kong, while the exercise intervention will be conducted outdoors in a small group setting (3-5 participants). 2. three-time-per-week moderate-intensity (\~3.5 mets) or vigorous-intensity (\~7 mets) walking exercise will be prescribed to participants in two exercise groups, while the participants in the waitlist group will receive no intervention. the intervention duration is 12 weeks. 3. we will recruit participants from the community in hk. interested participants will be invited for a semi-structured interview including an assessment on the beck depression inventory and medical history record to confirm eligibility.


Eligibility criteria:
inclusion criteria: 1. older adults aged equal or over 50 years; 2. ethnic chinese; 3. beck depression inventory score over 9 points; 4. diagnosed with mdd and currently on pharmacological treatment for mdd. exclusion criteria: 1. incapable of participating in physical exercise with major confounding conditions which are known to affect mobility; 2. cannot walk without assistive device; 3. regular exercise habit (defined as exercise \> 3 times per week and each time \> 50 minutes) 4. any serious somatic condition that prevents walking exercise participation (such as limb loss) 5. history of major diseases e.g. cancer, cardio-/cerebrovascular, neurodegenerative and renal diseases; 6. diagnosis of dementia/alzheimer's disease, or currently using antidementia medication;

Keywords: mdd, walking exercise, exercise intensity
comparison of diagnostic performance of medical monitor and medical augmented reality glasses in endoscopy: observation study

Conditions: Early Gastric Cancer

Summary: the purpose of this study was to compare the outcomes of medical augmented reality glasses and general monitors when distinguishing mucosal lesions from submucosal lesions in endoscopic diagnosis for early gastric cancer.


Eligibility criteria:
inclusion criteria: * patients with early gastric cancer who are scheduled for endoscopic submucosal dissection * age 19 or more * patients who voluntarily participated in this clinical study and signed a written informed consent exclusion criteria: * patients with poor general medical condition which does not allow them to understand and submit a informed consent * patients who do not agree with this study
safety and efficacy of pramipexole and bromocriptine combined with l-dopa in parkinson's disease

Conditions: Parkinson Disease

Summary: the objective of the study was to evaluate the efficacy and safety of snd 919 (pramipexole) tablets administered in combination with l-dopa in patients with parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase iii comparative study).


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of parkinson's disease (including juvenile parkinsonism) * patients who meet all of the following inclusion criteria * patients who were at least 20 years of age * in- or outpatients of either sex * patients in any stage on the modified hoehn and yahr scale * patients being treated with l-dopa who have any of the following clinical conditions and problems * patients with the wearing-off phenomenon * patients with the on-off phenomenon * patients to whom a sufficient amount of l-dopa cannot be administered owing to the occurrence of an adverse event * patients in whom the effect of l-dopa is attenuated * patients in whom a dose increase of l-dopa has been refrained * patients with freezing phenomenon exclusion criteria: * patients being treated with other dopamine agonists (bromocriptine, pergolide mesylate, talipexole hydrochloride). patients who have been treated with other dopamine agonist for at least 4 weeks before the start of the study (the day of giving informed consent) are eligible for the study * patients with a history of hypersensitivity to ergot preparations * patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour * patients with subjective symptoms derived from orthostatic hypotension * patients with hypotension (systolic blood pressure less than 100 mmhg) * patients wiht raynaud disease * patients with peptic ulcer * patients with complications such as severe cardiac, renal, hepatic disease etc. * patients with a current or past history of epilepsy * women who are or may be pregnant and lactating women * patients who are receiving any other investigational products or who have received any other investigational product within 6 months of the study * patients who are incompetent to give consent * others judged by the investigator or co-investigator to be ineligible as subjects
clinic versus home spirometry

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: the study aims to assess the differences between spirometry performed with the nuvoair air next spirometer in the clinic setting with both direct and virtual supervision via a video call, and in the home setting with virtual supervision. this is will be achieved by comparing lung function values, specifically the fev1 and fvc measurements. we also wish to evaluate participant's perceptions of home spirometry, by using a survey. this is a multi-centre, cross-over study. the study will enrol participants with a diagnosis of asthma and copd, across participating study sites until 68 have completed the study.


Eligibility criteria:
inclusion criteria: * an ability to provide fully informed consent. * a diagnosis of asthma or copd. * male or female aged ≥18 and ≤ 80 years of age. exclusion criteria: * symptoms suggestive of covid-19. * an exacerbation of asthma or copd or symptoms of a respiratory infection within the 30 days prior to the first visit. * any other clinically significant medical disease or uncontrolled concomitant disease, that is likely, in the opinion of the investigator(s), to impact on the ability to participate in the study. * the presence of any contraindications to spirometry.
peristomal hernia rate 5 years after a terminal colostomy with the parietex ™ tcm parietal prosthesis versus without mesh

Conditions: Colostomy Stoma; Parastomal Hernia

Summary: this study is a follow-up of the greccar 07 cohort (nct01380860). patients will be evaluated 5 years following terminal colostomy to observe patient long-term patient outcomes from colostomy with and without mesh placement.


Eligibility criteria:
inclusion criteria: * the patient must be affiliated with a health insurance programme * patient was included in the greccar 07 cohort (phrc national 2011; n° rcb: 2011-a01572-39 - clinicaltrials.gov id: nct01380860) * patient received colostomy 5 years ago exclusion criteria: * the subject is participating in another category i interventional study, or is in a period of exclusion determined by a previous study * the subject signals opposition to participating in the study * the patient is under safeguard of justice or state guardianship * the patient is pregnant or breastfeeding
survey study: financial impact of breast cancer treatment

Conditions: Breast Cancer

Summary: a survey study to evaluate the financial impact of breast cancer as self-reported by breast cancer patients over a period of 1 year. the study will also look at the health insurance literacy and patient's utilization of support services.


Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosed with breast cancer or a recurrence of breast cancer within the past 2 years * willing to sign consent * able to read and complete surveys in english exclusion criteria: * cancer diagnosis other than breast cancer * more than 2 years since diagnosis with breast cancer or recurrence
carotid atherosclerosis in patients with aortic coarctation

Conditions: Atherosclerosis; Aortic Coarctation

Summary: despite aortic coarctation (coa) repair these patients have cardiovascular complications and coronary artery disease is the most common cause of death.

the aim with this study was to measure intima-media thickness (imt) and plaques in arteries compared to cardiovascular markers in controls and patients with coa.

Eligibility criteria:
inclusion criteria: * sex and age-matched controls exclusion criteria: * acute and chronic inflammation disease, underlying malignancies and diabetes mellitus.
short term feeding for asian patients with liver cirrhosis

Conditions: CIRRHOSIS

Summary: the benefits of short-term naso-gastric feeding in patients with advanced cirrhosis remain uncertain. this was a randomised study comparing naso-gastric feeding and oral feeding in asian patients with cirrhosis who were admitted to hospital for decompensation.

consecutive patients with decompensated cirrhosis who fitted the inclusion criteria, will be randomised to either naso-gastric or oral feeding. total feeding will be for 2 weeks only. following intervention specific nutritional and liver-related parameters will be measured during the 2 weeks and up to 6 weeks later. comparison between both groups will then be made.

Eligibility criteria:
inclusion criteria: * patients with decompensated cirrhosis of any etiology. exclusion criteria: * advanced hepatic encephalopathy, * variceal bleeding, * hepatocellular carcinoma.

Keywords: cirrhosis malnutrition enteral nutrition
potential diagnostic and prognostic value of micrornas for the patients of sepsis-induced myocardial injury

Conditions: Sepsis-induced Myocardial Injury

Summary: the purpose of this study is to evaluate the potential diagnostic and prognosis value of circulating micrornas compared with ctni for the patients of sepsis-induced myocardial injury at the emergency department (ed) and intensive care unit (icu).


Eligibility criteria:
inclusion criteria: 1. diagnosis of sepsis:sofa score increase \>=2 at baseline level induced by infection. 2. suspected myocardial injury,including 1 as follows at least:low blood pressure or using vasoactive drugs; ecg changes(st segment changes or pathological q wave); troponin elevation(\> 0.5 μg/l); bnp elevation(\> 4670pg/ml); echocardiography: cardiac function decline(ef\<50%). exclusion criteria: 1. skeletal muscle damage (induced by orthopedics, vascular surgery or trauma surgical disease, surgery); 2. pregnant and lactating women; 3. patients with mental disorders; 4. patients are using other experimental drugs; 5. refusal to provide informed consent
an emotional regulation brief procedure (pbre) for fibromyalgia using ict's

Conditions: Fibromyalgia; Chronic Pain

Summary: the study aims is to test the efficacy of an emotional regulation procedure for fibromyalgia patients using information and communications technologies (icts). this procedure is based in a task that implies exposition to emotional words. the principal hypothesis is that exposition will improve the clinical symptomatology because the procedure restore an adequate emotional regulation.

previous studies have demonstrated that fm patients have difficulties to process emotional words when they are compared to normal subjects (mercado et al., 2013). this dysfunctional emotion regulation could show attentional bias and it could be a way to increase fm symptomatology as pain, and fatigue (duscheck et al., 2014). the emotion generation and its regulation through an experimental task as reading words is a well stablished procedure (lang, bradley y cuthbert, 1997). this paradigm has been shown efficacy in clinical context, to reduce anxiety in social phobia (masia et al., 1999; baños, quero y botella, 2008), generalized anxiety disorders (fracalanza, kroner y antony, 2014), personality disorders (arntz et al., 2012), and depression (chuang et al., 2016). to address the gap between the experimental results of this form of emotional regulation in fm patients, and its clinical application, the aim of this study is to evaluate the efficacy of a brief procedure of emotional regulation for fibromyalgia (pbre) pbre is a word reading task implementing through an app developed for smartphones. the patient will choose emotional positive and negative words related to personal and clinical characteristics. this exercise has been shown useful in analogous tasks in relational frame theory (hussey y barnes-holmes (2012) or in bias computer training (salemink et al., 2014).

Eligibility criteria:
inclusion criteria: * met the american college of rheumatology (acr) 2010 research classification criteria for fm (wolfe et al., 2010, 2011); as confirmed by a rheumatologist * a minimum of 18 years of age * showed adequate reading comprehension * were able to use a smartphone * were able to sign an informed consent form. exclusion criteria: * had any mental disorder treated by a psychiatrist * were scheduled for surgery in the next 3 months.
occupational exposure to dust and the relationship with the respiratory symptoms, lung function among construction workers of the university of malaysia sabah (ums)

Conditions: Occupational Exposure

Summary: background the respiratory tract often becomes the site of injury from occupational exposure. all construction sites generate high levels of dust, typically from concrete, silica, asbestos, cement, wood, stone, sand and therefore, the workers are exposed to this airborne dust and increased their risk of developing respiratory disorders. limited studies have been conducted to assess the relationship between respiratory symptoms, lung function and occupational dust exposure among construction workers in sabah. the objectives of this study are to determine the occupational exposure to dust and the relationship with the respiratory symptoms as well as lung function among construction workers in ums teaching hospital. materials and methods this cross-sectional study consisted of construction workers working in all sections in the development of ums teaching hospital. a standard respiratory questionnaire was distributed to construction workers and lung function measurement was performed using spirometry and the results of their respiratory status were compared between workers who were exposed and unexposed to dust. occupational dust exposure was determined by the gravimetric method using an air sampler. the total duration of the collection was 8 hours and the filters with the dust samples were analyzed in the laboratory.


Eligibility criteria:
inclusion criteria: * all construction worker exclusion criteria: * has chronic lung impairment

Keywords: occupational exposure, air pollution, lung function
novel treatment for port wine stain birthmarks

Conditions: Port-Wine Stain

Summary: port wine stains birthmark are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of newborns. approximately 1.5 million individuals in the united states and 32 million people worldwide have port wine stains birthmarks. two-thirds of these malformations occur on the face. personality development of virtually all patients is adversely affected as a result of the negative reaction of others to a "marked" person. detailed studies have documented lower self-esteem and difficulties with interpersonal interactions in port wine stains patients. port wine stains are initially flat and red, but with time, they tend to darken to purple and become thickened as vascular nodules develop. this thickening occurs in approximately two-thirds of lesions and further disfigures the facial features of many patients.

pulsed dye laser is currently the standard of care treatment for port wine stains. researchers at university of california irvine at beckman laser institute medical clinic can use photodynamic therapy, another treatment option for port wine stains. photodynamic therapy involves light activation of a photosensitizer (a drug that is responsive to light or radiant energy). because the photosensitizer can be localized to a desired portion of the port wine stain, photodynamic therapy creates an opportunity for targeted destruction of port wine stains. researchers will use a photosensitizer medication called talaporfin sodium, an intravenously administered investigational photosensitizer, being evaluated for multiple clinical indications. photodynamic therapy with talaporfin sodium has been investigated for many different conditions, and can be used for treatment for port wine stains. photosensitivity precaution instructions will be provided, including appropriate photo protective clothing, protective hat and sunglasses that wrap around the temples to help minimize lateral sun light exposure when traveling home following discharge from the study site. for efficacy, evaluated study variable will be port wine stain blanching, and the researchers can use diffuse reflectance imaging chromametry, laser speckle imaging and spatial frequency domain imaging to measure the change of port wine stain blanching. the maximum power of the laser speckle imaging and spatial frequency domain imaging light source is 10-50 mw, which is comparable to halogen-bulb household flashlights. efficacy will be evaluated based on comparison of pre-treatment visit and post treatment day 1, week 1, week 4, and week 12 measurements.

Eligibility criteria:
inclusion criteria: * male/female 18 years and older * have port wine stain birthmarks non-facial exclusion criteria: * under 18 years of age * no port wine stain birthmarks * pregnant/breast feeding

Keywords: port wine stain birthmarks
effect of low-dose vs. high-dose pitavastatin on in-stent restenosis

Conditions: Atherosclerosis; Neointima; Angina

Summary: to compare low dose (1mg) pitavastatin and high dose (4mg) pitavastatin on neointimal hyperplasia and atherosclerosis progression by using optical coherence tomography (oct) and near-infrared spectroscopy (nirs) at 12 months follow-up and on clinical adverse cardiovascular events during 3-year follow-up.

* patients with non-st elevation acs will be randomized into pitavastatin 1mg or 4mg after everolimus-eluting stent implantation with oct and nirs study. * 12 months follow-up coronary angiography with oct and nirs will be performed to compare neointimal hyperplasia and atherosclerosis progression. * 36 months clinical follow-up for major adverse cardiovascular events (cardiac death, all-cause death, myocardial infarction, stroke, target lesion revascularization) will be compared. * safety issues such as bleeding rates, abnormal liver function will be compared

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. patients between the age of 30 to 79 3. non-st elevation acute coronary syndrome with successful everolimus eluting stent implantation (with timi flow grade 3 after the procedure) exclusion criteria: 1. hypersensitivity to pitavastatin 2. unable to perform oct and nirs 3. serum creatinine \> 2.0 mg/dl. 4. steroid or hormone replacement therapy 5. hemoglobin a1c \>9% 6. type 1 diabetes 7. decreased serum platelet level (\< 100,000/ul) 8. need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin 9. life expectancy less than a year 10. renal failure requiring dialysis or anticipated need for dialysis during the course of the study 11. any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study 12. involvement in the planning and/or conduct of the study 13. left ventricular ejection fraction \< 40% 14. hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit) 15. gastrointestinal disorder such as crohn's disease 16. alcohol abuse 17. known pregnancy, breast-feeding, or intend to become pregnant during the study period
real world data analysis of parp inhibitors use in patients with ovarian cancer

Conditions: Ovarian Cancer

Summary: real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive parp inhibitors.

a prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.

Eligibility criteria:
inclusion criteria: - women \>18 years old with advanced high grade ovarian cancer exclusion criteria: -